Literature DB >> 29794876

Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease.

Vineet S Rolston, Anish V Patel1, Thomas J Learch2, Dalin Li3, Dmitry Karayev4, Chadwick Williams3, Madhavi L Siddanthi4, Stephan R Targan3, Michael H Weisman4, Dermot P B McGovern3.   

Abstract

OBJECTIVES: Avascular necrosis (AVN) is associated with significant morbidity potentially causing severe pain and disability; patients with inflammatory bowel disease (IBD) have a higher prevalence of AVN compared with non-IBD populations. The purpose of our study was to determine the prevalence of AVN in our IBD population and to evaluate these subjects for the presence of clinical characteristics associated with AVN on computed tomography (CT) imaging.
METHODS: In 1313 IBD patients with abdomen/pelvis CT scans, we identified 27 patients (2.1%) with CT findings consistent with AVN. Through historical chart review, we confirmed that most patients had prior exposure to steroids, although 2 patients had no documented steroid exposure at all.
RESULTS: We found that 59% of the concurrent radiology reports did not comment on the presence of AVN, suggesting that incidental CT findings of AVN among IBD patients are likely underreported. Notably, we found that 63% of these cases had documented complaints of low-back and/or hip pain. Using logistic regression, we found an association between anti-neutrophil cytoplasmic antibody-positive status across IBD (p = 0.007) and a smoking history in Crohn disease (p = 0.03) with the presence of AVN.
CONCLUSIONS: We found that a significant proportion of IBD patients with AVN are reported in their records as having hip or low-back pain, and review of CT imaging under dedicated bone windows may identify AVN among this population. Our findings also suggest that additional etiological factors, beyond corticosteroids, contribute to the development of AVN in IBD. Further investigation is warranted regarding the mechanisms associated with AVN in IBD.

Entities:  

Mesh:

Year:  2019        PMID: 29794876      PMCID: PMC6252167          DOI: 10.1097/RHU.0000000000000797

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  16 in total

1.  Clinically occult avascular necrosis of the hip: prevalence in an asymptomatic population at risk.

Authors:  O Tervonen; D M Mueller; E L Matteson; J A Velosa; W W Ginsburg; R L Ehman
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

2.  Steroid-related osteonecrosis in inflammatory bowel disease.

Authors:  N Vakil; M Sparberg
Journal:  Gastroenterology       Date:  1989-01       Impact factor: 22.682

3.  Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease.

Authors:  Dermot P B McGovern; Michelle R Jones; Kent D Taylor; Kristin Marciante; Xiaofei Yan; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Dror Berel; Carrie Derkowski; Deb Dutridge; Phil Fleshner; David Q Shih; Gil Melmed; Emebet Mengesha; Lily King; Sheila Pressman; Talin Haritunians; Xiuqing Guo; Stephan R Targan; Jerome I Rotter
Journal:  Hum Mol Genet       Date:  2010-06-22       Impact factor: 6.150

Review 4.  Non-traumatic avascular necrosis of the femoral head.

Authors:  M A Mont; D S Hungerford
Journal:  J Bone Joint Surg Am       Date:  1995-03       Impact factor: 5.284

5.  Genome-wide association identifies multiple ulcerative colitis susceptibility loci.

Authors:  Dermot P B McGovern; Agnès Gardet; Leif Törkvist; Philippe Goyette; Jonah Essers; Kent D Taylor; Benjamin M Neale; Rick T H Ong; Caroline Lagacé; Chun Li; Todd Green; Christine R Stevens; Claudine Beauchamp; Phillip R Fleshner; Marie Carlson; Mauro D'Amato; Jonas Halfvarson; Martin L Hibberd; Mikael Lördal; Leonid Padyukov; Angelo Andriulli; Elisabetta Colombo; Anna Latiano; Orazio Palmieri; Edmond-Jean Bernard; Colette Deslandres; Daan W Hommes; Dirk J de Jong; Pieter C Stokkers; Rinse K Weersma; Yashoda Sharma; Mark S Silverberg; Judy H Cho; Jing Wu; Kathryn Roeder; Steven R Brant; L Phillip Schumm; Richard H Duerr; Marla C Dubinsky; Nicole L Glazer; Talin Haritunians; Andy Ippoliti; Gil Y Melmed; David S Siscovick; Eric A Vasiliauskas; Stephan R Targan; Vito Annese; Cisca Wijmenga; Sven Pettersson; Jerome I Rotter; Ramnik J Xavier; Mark J Daly; John D Rioux; Mark Seielstad
Journal:  Nat Genet       Date:  2010-03-14       Impact factor: 38.330

6.  Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses.

Authors:  J H Klippel; L H Gerber; L Pollak; J L Decker
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

7.  Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients.

Authors:  Matthew F Dilisio
Journal:  Orthopedics       Date:  2014-07       Impact factor: 1.390

8.  Higher revision and complication rates following total hip arthroplasty in patients with inflammatory bowel disease.

Authors:  Bhaveen H Kapadia; Kimona Issa; Nupur Nagrare; Robert Pivec; Samik Banerjee; Michael A Mont
Journal:  J Arthroplasty       Date:  2013-11-11       Impact factor: 4.757

9.  Avascular necrosis of bone after cardiac transplantation. Prevalence and relationship to administration and dosage of steroids.

Authors:  G Bradbury; J Benjamin; J Thompson; E Klees; J Copeland
Journal:  J Bone Joint Surg Am       Date:  1994-09       Impact factor: 5.284

10.  Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication.

Authors:  Paola Caramaschi; Domenico Biasi; Ilaria Dal Forno; Silvano Adami
Journal:  Autoimmune Dis       Date:  2012-08-05
View more
  1 in total

1.  Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience.

Authors:  Khalil I Bourji; Christopher A Mecoli; Julie J Paik; Jemima Albayda; Eleni Tiniakou; William Kelly; Thomas E Lloyd; Andrew Mammen; Shivani Ahlawat; Lisa Christopher-Stine
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.